Mining Real-World Data to Identify Factors That Impact Payer Approvals

NASSCOM is inviting you to join a webinar on "Mining Real-World Data to Identify Factors That Impact Payer Approvals"on 15^th September from 4:00 PM- 5:00 PM.

Specialty drugs are playing an important role in the US market as pharma manufacturers continue to focus more on targeted therapies for smaller patient populations. Approximately 60% of the pipeline drugs awaiting approval from the U.S. Food and Drug Administration (FDA) in the next two years are specialty drugs. Since these drugs are very expensive, there are a lot of challenges in ensuring they reach the right set of patients. The pharma companies and other stakeholders in the market follow different strategies to navigate through the barriers.

In this webinar, we will cover some of the key tactics that are adopted by pharma companies. Webinar attendees can gain some valuable insight into how to leverage SP, HUB, and APLD data sets to uncover new evidence and improve patient well-being using Analytics and ML algorithms.

We will discuss in detail the following

• The path to specialty prescription starting with confirmation, benefit investigation, prior authorization, appeal in case of denial, financial assistance, and, finally, filling the prescription
• Why drug manufacturers want to have a closer connection with patients and how the HUB helps them reduce this gap
• Different real-world data sets available to us and factors to consider before selecting a particular data type for the analysis
• Finally, for our case study, we saw how we can combine multiple RWE data sets and execute a detailed analysis to identify different patient characteristics that payers look at before approving or rejecting a drug. Moreover, we saw how we can apply ML techniques to evaluate the outcomes and demonstrate the benefits of a drug to improve approval rates